- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02987387
COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction
October 27, 2023 updated by: Edwards Lifesciences
New Enrollment SAPIEN XT Post-Approval Study
This study will confirm the safety and effectiveness of the Edwards Lifesciences SAPIEN XT Transcatheter Heart Valve (THV) System in patients with a dysfunctional right ventricular outflow tract (RVOT) conduit with a clinical indication for intervention in a post-market setting.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The study is a prospective, non-randomized, multi-center clinical study to assess the safety and effectiveness of pulmonic implantation of the SAPIEN THV in patients with dysfunctional RVOT conduits requiring treatment for moderate or severe pulmonary regurgitation (PR) by transthoracic echocardiography (TTE) and/or RVOT conduit obstruction with a mean gradient of ≥ 35 mmHg by TTE.
Study Type
Observational
Enrollment (Actual)
57
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University Of Alabama
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Illinois
-
Oak Lawn, Illinois, United States, 60453
- Advocate Children's Hospital
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- The University of Iowa
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Children's Hospital of Michigan
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
- Children's Heart Center Nevada
-
-
New Jersey
-
Newark, New Jersey, United States, 07112
- Newark Beth Israel Medical Center
-
-
New York
-
New York, New York, United States, 10003
- Mount Sinai Beth Israel
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Pediatric and adult patients with a dysfunctional, non-compliant right ventricular outflow tract (RVOT) conduit with a clinical indication for intervention.
Description
Inclusion Criteria:
- Patient has a dysfunctional, non-compliant RVOT conduit.
- The patient/patient's legally authorized representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.
Exclusion Criteria:
- Inability to tolerate an anticoagulation/antiplatelet regimen
- Active bacterial endocarditis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
TPVI
Transcatheter Pulmonary Valve Implantation with the SAPIEN XT THV
|
SAPIEN XT THV will be implanted in the pulmonic position.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Freedom from device- or procedure-related death or reintervention
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in pulmonary regurgitation to mild or less for regurgitant lesions
Time Frame: 1 year
|
Assessed via transthoracic echocardiogram (TTE)
|
1 year
|
Decrease in RVOT mean gradient to less than 30 mmHg for stenotic lesions
Time Frame: 1 year
|
Assessed via TTE
|
1 year
|
Device Success
Time Frame: 48 Hours Prior to Discharge
|
Device Success is a composite of:
|
48 Hours Prior to Discharge
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 17, 2017
Primary Completion (Actual)
August 9, 2021
Study Completion (Estimated)
September 1, 2025
Study Registration Dates
First Submitted
October 19, 2016
First Submitted That Met QC Criteria
December 6, 2016
First Posted (Estimated)
December 8, 2016
Study Record Updates
Last Update Posted (Actual)
October 30, 2023
Last Update Submitted That Met QC Criteria
October 27, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Diseases
-
Baker Heart and Diabetes InstitutePrincess Alexandra Hospital, Brisbane, Australia; Royal Perth Hospital; Alice... and other collaboratorsRecruitingHeart Failure | Valve Heart DiseaseAustralia
-
Medical University of ViennaUnknownHeart Diseases | Heart Failure | Valvular Heart DiseaseAustria
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Kathirvel SubramaniamUniversity of Maryland, Baltimore; CSL BehringRecruitingHeart Failure,Congestive | Heart Disease End StageUnited States
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Yonsei UniversityCompletedMitral Valvular Heart Disease
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Heart Failure | Valvular Heart Disease | Biochemical DysfunctionGreece
-
University College, LondonBritish Heart Foundation; Horizon 2020 - European CommissionRecruitingValvular Heart DiseaseUnited Kingdom
Clinical Trials on SAPIEN XT THV
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Claret MedicalCompletedSevere Symptomatic Calcified Native Aortic Valve StenosisUnited States, Germany
-
Edwards LifesciencesRecruitingPulmonary Valve Insufficiency | Complex Congenital Heart Defect | Dysfunctional RVOT Conduit | Pulmonary Valve DegenerationUnited States
-
Edwards LifesciencesNot yet recruitingMitral Regurgitation | Mitral Valve Disease | Mitral Stenosis
-
Edwards LifesciencesRecruitingAortic Valve Stenosis | Aortic Valve InsufficiencyUnited States, Canada
-
Edwards LifesciencesRecruitingAortic Stenosis, SevereUnited States, Australia, New Zealand, Canada
-
Edwards LifesciencesRecruitingPulmonary Valve Insufficiency | Complex Congenital Heart Defect | Dysfunctional RVOT Conduit | Pulmonary Valve Degeneration | Pulmonary Valve; ObstructionUnited States
-
Edwards LifesciencesCompletedAortic Valve StenosisJapan
-
Edwards LifesciencesRecruitingAortic Stenosis | Aortic Stenosis, SevereUnited States, Canada
-
Institut für Pharmakologie und Präventive MedizinEstimate, GmbHCompleted